MX2015007518A - Metodos para tratar el prurito. - Google Patents

Metodos para tratar el prurito.

Info

Publication number
MX2015007518A
MX2015007518A MX2015007518A MX2015007518A MX2015007518A MX 2015007518 A MX2015007518 A MX 2015007518A MX 2015007518 A MX2015007518 A MX 2015007518A MX 2015007518 A MX2015007518 A MX 2015007518A MX 2015007518 A MX2015007518 A MX 2015007518A
Authority
MX
Mexico
Prior art keywords
methods
treating pruritus
pruritus
treating
relates
Prior art date
Application number
MX2015007518A
Other languages
English (en)
Spanish (es)
Inventor
Thomas Sciascia
Original Assignee
Trevi Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US13/715,625 external-priority patent/US8637538B1/en
Application filed by Trevi Therapeutics Inc filed Critical Trevi Therapeutics Inc
Publication of MX2015007518A publication Critical patent/MX2015007518A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
MX2015007518A 2012-12-14 2013-12-13 Metodos para tratar el prurito. MX2015007518A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261737488P 2012-12-14 2012-12-14
US13/715,625 US8637538B1 (en) 2012-12-14 2012-12-14 Methods for treatment of pruritis
PCT/US2013/075096 WO2014093871A1 (en) 2012-12-14 2013-12-13 Methods for treating pruritus

Publications (1)

Publication Number Publication Date
MX2015007518A true MX2015007518A (es) 2016-03-01

Family

ID=50935003

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015007518A MX2015007518A (es) 2012-12-14 2013-12-13 Metodos para tratar el prurito.

Country Status (13)

Country Link
EP (1) EP2931279B1 (enExample)
JP (4) JP2016506398A (enExample)
KR (3) KR20150093702A (enExample)
CN (2) CN110585209A (enExample)
AU (2) AU2013359017B2 (enExample)
BR (1) BR112015013984A2 (enExample)
CA (1) CA2892393C (enExample)
ES (1) ES2984559T3 (enExample)
MX (1) MX2015007518A (enExample)
NZ (1) NZ708371A (enExample)
RU (1) RU2015128265A (enExample)
WO (1) WO2014093871A1 (enExample)
ZA (2) ZA201504229B (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI433674B (zh) 2006-12-28 2014-04-11 Infinity Discovery Inc 環杷明（ｃｙｃｌｏｐａｍｉｎｅ）類似物類
JP2016506398A (ja) * 2012-12-14 2016-03-03 トレビ セラピューティクス インコーポレイテッド そう痒の処置法
US20140179727A1 (en) 2012-12-14 2014-06-26 Trevi Therapeutics, Inc. Methods for treating pruritus
AU2015274327A1 (en) * 2014-06-13 2017-01-05 Trevi Therapeutics, Inc. Methods for treating pruritus
CA2988289C (en) 2015-06-04 2023-12-05 PellePharm, Inc. Topical formulations for delivery of hedgehog inhibitor compounds and use thereof
TW201725041A (zh) * 2016-01-04 2017-07-16 懷特生技新藥股份有限公司 治療皮膚癢之醫藥組合物
CN105560202B (zh) * 2016-03-11 2019-05-24 广州玻思韬控释药业有限公司 一种盐酸纳布啡凝胶骨架缓释片的制备方法及应用
EP3432871B1 (en) * 2016-03-21 2023-11-15 Trevi Therapeutics, Inc. Treatment of uremic pruritus
EP3532061A4 (en) * 2016-10-25 2020-07-08 Trevi Therapeutics, Inc. TREATMENT OF PRURIGO NODULAR
JP7390695B2 (ja) * 2017-02-03 2023-12-04 株式会社東洋新薬 錠剤及び錠剤の製造方法
CN118477079A (zh) * 2018-07-23 2024-08-13 特雷维治疗股份有限公司 慢性咳嗽、呼吸急促和呼吸困难的治疗
WO2021142288A1 (en) 2020-01-10 2021-07-15 Trevi Therapeutics, Inc. Methods of administering nalbuphine

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2285733T3 (es) * 1996-11-25 2007-11-16 Toray Industries, Inc. Agente antipruritico.
US20030054030A1 (en) * 2001-09-13 2003-03-20 Gary Gordon Method and compositions for the treatment of pruritus
US6703398B2 (en) * 2001-11-26 2004-03-09 Oliver Yoa-Pu Hu Orally administered analgesic compositions containing nalbuphine
DK2425821T5 (en) * 2002-04-05 2018-02-12 Mundipharma As Pharmaceutical preparation containing oxycodone and naloxone
EP1763349A2 (en) * 2004-06-03 2007-03-21 Jonathan J. Burbaum Pharmaceutical compositions for the treatment of pruritus
US8394812B2 (en) * 2005-08-24 2013-03-12 Penwest Pharmaceuticals Co. Sustained release formulations of nalbuphine
ES2862573T3 (es) 2005-08-24 2021-10-07 Endo Pharmaceuticals Inc Formulaciones de nalbufina de liberación sostenida
FR2963889B1 (fr) * 2010-08-20 2013-04-12 Debregeas Et Associes Pharma Formulations a base de nalbuphine et leurs utilisations
JP2016506398A (ja) * 2012-12-14 2016-03-03 トレビ セラピューティクス インコーポレイテッド そう痒の処置法

Also Published As

Publication number Publication date
JP7072280B2 (ja) 2022-05-20
ZA201504229B (en) 2021-07-28
EP2931279A4 (en) 2016-05-11
WO2014093871A1 (en) 2014-06-19
CN110585209A (zh) 2019-12-20
JP2019131588A (ja) 2019-08-08
KR20150093702A (ko) 2015-08-18
ZA201906339B (en) 2021-07-28
AU2018214098B2 (en) 2019-04-18
KR20220044385A (ko) 2022-04-07
NZ708371A (en) 2020-05-29
AU2013359017B2 (en) 2018-05-10
AU2018214098A1 (en) 2018-08-30
HK1215541A1 (en) 2016-09-02
JP6823857B2 (ja) 2021-02-03
EP2931279A1 (en) 2015-10-21
RU2015128265A (ru) 2017-01-25
CA2892393C (en) 2021-06-08
KR20210050585A (ko) 2021-05-07
CA2892393A1 (en) 2014-06-19
EP2931279B1 (en) 2024-03-20
JP2016506398A (ja) 2016-03-03
JP2022105095A (ja) 2022-07-12
BR112015013984A2 (pt) 2017-07-11
ES2984559T3 (es) 2024-10-29
AU2013359017A1 (en) 2015-06-11
JP2021020947A (ja) 2021-02-18
CN104981246A (zh) 2015-10-14

Similar Documents

Publication Publication Date Title
MX2015007518A (es) Metodos para tratar el prurito.
MX2015012401A (es) Composiciones y metodos de alterar niveles de colesterol.
SG11201506944WA (en) Betaine compounds as additives for fuels
MX2015002487A (es) Proceso para la preparacion de teneligliptina.
IN2013DE00266A (enExample)
IN2014DN08777A (enExample)
SG11201509341VA (en) Fuel additive composition
EP2994542A4 (en) Compositions for ovarian cancer assessment having improved specificity
IN2013MU01113A (enExample)
IN2014CH00151A (enExample)
PH12016501183A1 (en) Novel compound for treatment of severe hypoglycemia
UA117567C2 (uk) Композиція, яка стимулює лактацію, на основі фосфатидилсерину
IN2015DN00725A (enExample)
IN2014DN10209A (enExample)
PH12016501184A1 (en) Novel compound for treatment of severe hypoglycemia
PH12016501182A1 (en) Novel compound for treatment of severe hypoglycemia
GB201322176D0 (en) Fuel additive composition
MX2013002111A (es) Metodos y composiciones para el tratamiento de metastasis del cancer.
IN2013MU03768A (enExample)
MY171860A (en) Method for purifying a crude pnpnh compound
GB201222425D0 (en) Fuel additive composition
IN2015DN01285A (enExample)
IN2015KN00386A (enExample)
UA80618U (en) Use of n-steroylethanolamine as radiomodifier
UA106373C2 (ru) Применение поллентара как средства фригопротекторного действия